Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
CDT CDT Equity	$1.33 -1.5%	$2.07	$1.29 ▼ $274.80	$4.07M	1.93	303,294 shs	144,599 shs
CPHI China Pharma	$1.39 -2.0%	$1.65	$1.20 ▼ $3.35	$4.54M	0.87	104,880 shs	15,246 shs
ONCO Onconetix	$2.93 -2.3%	$3.69	$2.61 ▼ $552.50	$4.54M	3.37	371,878 shs	19,886 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CDT CDT Equity	-5.59%	-12.34%	-28.19%	-59.09%	-99.36%
CPHI China Pharma	+0.29%	-5.14%	-19.31%	-12.25%	-92.94%
ONCO Onconetix	+2.04%	+6.76%	-17.13%	-52.24%	-99.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDT CDT Equity	0.2252 of 5 stars	0.0	3.0	0.0	0.0	2.2	0.0	0.0
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	1.1059 of 5 stars	0.0	4.0	0.0	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A
CDT CDT Equity	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
CDT CDT Equity	N/A	N/A	N/A	N/A	$1.15 per share	N/A
CPHI China Pharma	$4.40M	1.03	N/A	N/A	$0.70 per share	1.99
ONCO Onconetix	$2.52M	1.80	N/A	N/A	$3.82 per share	0.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
CDT CDT Equity	-$17.80M	-$435.00	N/A	∞	N/A	N/A	N/A	-350.23%	11/12/2025 (Estimated)
CPHI China Pharma	-$3.08M	N/A	0.00	∞	N/A	-85.56%	-63.93%	-31.42%	N/A
ONCO Onconetix	-$58.69M	N/A	0.00	∞	N/A	-3,327.03%	-192.74%	-89.55%	N/A

Latest ASLN, ONCO, CDT, and CPHI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CDT CDT Equity	N/A	-$5.46	N/A	-$5.46	N/A	N/A
8/14/2025	Q2 2025	ONCO Onconetix	N/A	-$4.05	N/A	-$4.76	N/A	$0.11 million
6/12/2025	Q1 2025	ONCO Onconetix	N/A	$21.25	N/A	-$0.53	N/A	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDT CDT Equity	N/A	N/A	N/A	N/A	N/A
CPHI China Pharma	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
CDT CDT Equity	N/A	1.45	1.45
CPHI China Pharma	0.22	0.79	0.26
ONCO Onconetix	N/A	0.07	0.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
CDT CDT Equity	3.29%
CPHI China Pharma	N/A
ONCO Onconetix	23.89%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
CDT CDT Equity	7.72%
CPHI China Pharma	17.32%
ONCO Onconetix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
CDT CDT Equity	3	3.06 million	2.83 million	Not Optionable
CPHI China Pharma	250	3.26 million	15.92 million	Not Optionable
ONCO Onconetix	12	1.55 million	1.50 million	N/A

ASLN, ONCO, CDT, and CPHI Headlines

Recent News About These Companies

Onconetix Director Resignation Amid Financial Adjustments

August 12, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)

July 17, 2025 | globenewswire.com

Onconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

July 16, 2025 | finanznachrichten.de

Onconetix Shares Touch All-Time Low on Reverse Merger With Ocuvex

July 16, 2025 | marketwatch.com

ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders

July 16, 2025 | businesswire.com

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

July 16, 2025 | globenewswire.com

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

June 16, 2025 | globenewswire.com

Onconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by Stockholders

June 13, 2025 | nasdaq.com

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

June 11, 2025 | globenewswire.com

Onconetix faces potential Nasdaq delisting over filing delays

May 24, 2025 | investing.com

Onconetix receives additional delisting notice from Nasdaq

May 23, 2025 | finance.yahoo.com

Onco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision Oncology

May 22, 2025 | accessnewswire.comA

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025 | globenewswire.com

Onco-Innovations Uplists to Cboe Canada

May 22, 2025 | businesswire.com

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

April 30, 2025 | globenewswire.com

Onconetix faces third delisting threat since 2022 IPO

April 21, 2025 | bizjournals.com

Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology

April 17, 2025 | accessnewswire.comA

Onco-Innovations Announces Private Placement

April 16, 2025 | accessnewswire.comA

Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex

April 10, 2025 | nasdaq.com

Five things you need to know today, and calming irrational fears

April 9, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN, ONCO, CDT, and CPHI Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/28/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

CDT Equity NASDAQ:CDT

$1.33 -0.02 (-1.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 -0.02 (-1.13%)

As of 05:17 PM Eastern

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

China Pharma NYSE:CPHI

$1.39 -0.03 (-2.04%)

Closing price 03:55 PM Eastern

Extended Trading

$1.38 -0.01 (-0.43%)

As of 04:10 PM Eastern

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Onconetix NASDAQ:ONCO

$2.93 -0.07 (-2.33%)

Closing price 03:59 PM Eastern

Extended Trading

$3.00 +0.06 (+2.22%)

As of 05:04 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time